A Single-Site, In-Clinic Study Evaluating Short-Term Safety, Tolerability And Pharmacokinetic Of VK5211 In Healthy Elderly Subjects Aged 65 Years And Older.

Trial Profile

A Single-Site, In-Clinic Study Evaluating Short-Term Safety, Tolerability And Pharmacokinetic Of VK5211 In Healthy Elderly Subjects Aged 65 Years And Older.

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2016

At a glance

  • Drugs VK 5211 (Primary)
  • Indications Hip fracture
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 10 Nov 2016 Results presented at the 5th Fragility Fracture Network (FFN) Global Congress 2016, according to a Viking Therapeutics media release.
    • 01 Sep 2016 Results published in the Media Release
    • 01 Sep 2016 Results from this trial will be presented the 5th Fragility Fracture Network (FFN) Global Congress 2016, as reported in a Viking Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top